Search hospitals > Pennsylvania > York
WellSpan Health-York Hospital
Claim this profileYork, Pennsylvania 17403
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
263 reported clinical trials
17 medical researchers
Summary
WellSpan Health-York Hospital is a medical facility located in York, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. WellSpan Health-York Hospital is involved with conducting 263 clinical trials across 304 conditions. There are 17 research doctors associated with this hospital, such as Chanh T. Huynh, Amit B. Shah, Dan Sotirescu, and Joseph Kannarkatt.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Chanh T. HuynhAdams Cancer Center1 year of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
19 reported clinical trials
37 drugs studied
Amit B. ShahWellSpan Health-York Cancer Center9 years of reported clinical research
Studies Prostate Cancer
Studies Small Cell Lung Cancer
19 reported clinical trials
61 drugs studied
Dan SotirescuEphrata Cancer Center4 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
28 drugs studied
Joseph KannarkattWellSpan Medical Oncology and Hematology3 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
31 drugs studied
Clinical Trials running at WellSpan Health-York Hospital
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Heart Failure
Small Cell Lung Cancer
Lung Carcinoma
Pancreatic Cancer
Recurrence
ALK Gene Rearrangement
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Imlunestrant
for Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at WellSpan Health-York Hospital?
WellSpan Health-York Hospital is a medical facility located in York, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. WellSpan Health-York Hospital is involved with conducting 263 clinical trials across 304 conditions. There are 17 research doctors associated with this hospital, such as Chanh T. Huynh, Amit B. Shah, Dan Sotirescu, and Joseph Kannarkatt.